Albireo Pharma Inc Revenue Q/Q
What is the Revenue Q/Q of Albireo Pharma Inc?
The Revenue Q/Q of Albireo Pharma Inc is 168.34%
What is the definition of Revenue Q/Q?
Quarterly revenue growth, year over year, is the increase of a company’s revenue compared to the performance in the corresponding quarter of a previous year expressed as a percentage.
quarterly growth yoy (year over year)
Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.
Revenue Q/Q of companies in the Health Care sector on NASDAQ compared to Albireo Pharma Inc
What does Albireo Pharma Inc do?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Companies with revenue q/q similar to Albireo Pharma Inc
- Judo Capital Ltd has Revenue Q/Q of 166.99%
- Page Industries has Revenue Q/Q of 167.43%
- Safe-T Ltd has Revenue Q/Q of 167.77%
- TRF has Revenue Q/Q of 167.80%
- Urbanimmersive has Revenue Q/Q of 168.00%
- Lonestar Resources US Inc has Revenue Q/Q of 168.03%
- Albireo Pharma Inc has Revenue Q/Q of 168.34%
- NEXT Biometrics ASA has Revenue Q/Q of 169.02%
- EPI () has Revenue Q/Q of 169.03%
- Teranga Gold has Revenue Q/Q of 169.44%
- Teranga Gold has Revenue Q/Q of 169.45%
- Jindal Drilling & Industries has Revenue Q/Q of 170.01%
- Score Media And Gaming Inc has Revenue Q/Q of 170.17%